Trishna Goswami
Directeur Technique/Scientifique/R&D chez IN8BIO, INC.
Fortune : 5 693 $ au 30/06/2024
Profil
Dr. Trishna Goswami is a Chief Medical Officer at IN8bio, Inc. Dr. Goswami was previously employed as a Vice President-Clinical Development by Immunomedics, Inc., a Senior Director-Medical by Stemline Therapeutics, Inc., and a Vice President-Clinical Development by Gilead Sciences, Inc. She received her MBA from Robert H.
Smith School of Business and a doctorate degree from Drexel University College of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IN8BIO, INC.
0,02% | 17/04/2024 | 6 729 ( 0,02% ) | 5 693 $ | 30/06/2024 |
Postes actifs de Trishna Goswami
| Sociétés | Poste | Début |
|---|---|---|
| IN8BIO, INC. | Directeur Technique/Scientifique/R&D | 16/11/2021 |
Anciens postes connus de Trishna Goswami
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 01/12/2021 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Formation de Trishna Goswami
| Drexel University College of Medicine | Doctorate Degree |
| Robert H. Smith School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
